Cargando…

Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China

Background: Fulvestrant 500mg has proved its clinical effectiveness in previous trials as primary or second line treatment of hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2˗) post-menopausal advanced breast cancer. This real-world study aimed to investigate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Wen, Li, Huiping, Song, Guohong, Zhang, Ruyan, Ran, Ran, Yan, Ying, Di, Lijun, Jiang, Hanfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545684/ https://www.ncbi.nlm.nih.gov/pubmed/33046982 http://dx.doi.org/10.7150/jca.47960

Ejemplares similares

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
por: Palumbo, Raffaella, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
por: Telford, Claire, et al.
Publicado: (2019)

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
por: Leo, Angelo Di, et al.
Publicado: (2013)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
por: Robertson, John F. R., et al.
Publicado: (2019)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
por: Li, Junjie, et al.
Publicado: (2019)

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
por: Robertson, John FR, et al.
Publicado: (2013)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
por: Zhang, Qingyuan, et al.
Publicado: (2016)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2021)

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
por: Sabale, Ugne, et al.
Publicado: (2017)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study
por: Zhang, Ruyan, et al.
Publicado: (2021)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
por: Masuda, Norikazu, et al.
Publicado: (2018)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
por: Neven, Patrick, et al.
Publicado: (2021)

Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review
por: Chu, Zhaohui
Publicado: (2022)

The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis
por: Zhang, Linhui, et al.
Publicado: (2021)

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
por: Torrisi, Rosalba, et al.
Publicado: (2022)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer
por: Li, Huiping, et al.
Publicado: (2021)

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
por: Ellis, Matthew J., et al.
Publicado: (2015)

Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States
por: Caldeira, Rita, et al.
Publicado: (2016)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
por: Inoue, Kenichi, et al.
Publicado: (2021)

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)
por: Jiang, Hanfang, et al.
Publicado: (2021)

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients
por: Iwata, Hiroji, et al.
Publicado: (2017)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
por: Sammons, Sarah, et al.
Publicado: (2018)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
por: Xu, Liang, et al.
Publicado: (2018)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
por: Tibau, Ariadna, et al.
Publicado: (2023)

Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series
por: Huang, Jian, et al.
Publicado: (2020)

Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report
por: Gui, Xinyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_inm3oa12dghmht7so5jjopha6c